Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1158/2159-8290.CD-16-0999

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:37046636

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax

Joan Montero1, Jason Stephansky1, Tianyu Cai2, Gabriel K. Griffin3, Lucia Cabal-Hierro1, Katsuhito Togami1, Leah J. Hogdai1, Ilene Galinsky4, Elizabeth A. Morgan3, Jon C. Aster3, Matthew S. Davids1, Nicole R. LeBoeuf4, Richard M. Stone1, Marina Konopleva2, Naveen Pemmaraju2, Anthony Letai1, and Andrew A. Lane1,5

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
3Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
4Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA
5Broad Institute of Harvard and MIT, Cambridge, MA

*These authors contributed equally
#These authors contributed equally

Correspondence
Lead contact:
Andrew Lane, MD, PhD
Dana-Farber Cancer Institute
450 Brookline Ave, Mayer 413
Boston, MA 02215
617-632-4589
andrew_lane@dfci.harvard.edu

Naveen Pemmaraju, MD
University of Texas
MD Anderson Cancer Center
Unit 428, PO Box 301402
Houston, TX 77230
713-792-4956
npemmaraju@mdanderson.org

Anthony Letai, MD, PhD
Dana-Farber Cancer Institute
450 Brookline Ave, Mayer 430
Boston, MA 02215
617-582-7254
anthony_letai@dfci.harvard.edu

Disclosures: R.M.S. is a consultant for AbbVie and Genentech/Roche. A.A.L received research support from Stemline Therapeutics.

Running title: Venetoclax in blastic plasmacytoid dendritic cell neoplasm
Keywords: BPDCN, BCL-2, venetoclax, leukemia, BH3 profiling
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the anti-apoptotic protein BCL-2 and were uniformly sensitive to the BCL-2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on two patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL-2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker.

Statement of significance
Therapy for BPDCN is inadequate and survival in patients with the disease is poor. We used primary tumor cell functional profiling to predict BCL-2 antagonist sensitivity as a common feature of BPDCN, and demonstrated in vivo clinical activity of venetoclax in patient-derived xenografts and in two patients with relapsed chemotherapy-refractory disease.
**Introduction**

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration (1). There is no standard therapy and patients empirically receive chemotherapy regimens based on retrospective case series (2). For patients who respond to chemotherapy, autologous or allogeneic stem cell transplantation may prolong survival (3). However, median survival is only approximately one year, or even shorter in patients who have disseminated disease (1,2).

BPDCN has had many prior names, including CD4+CD56+ hematodermic neoplasm, blastic natural killer cell lymphoma, and agranular CD4+ natural killer cell leukemia, which has complicated study of the disease (1). In 2008, BPDCN was recognized as the malignant counterpart of plasmacytoid dendritic cells (pDCs) (4). However, the pathogenesis underlying the transformation of hematopoietic progenitors to BPDCN remains unclear. Targeted sequencing identified mutated genes in BPDCN that overlap with those observed in other hematologic malignancies, particularly myeloid diseases, including \textit{TET2}, \textit{TP53}, \textit{ASXL1}, and RNA splicing factors (5,6). However, no BPDCN-specific mutations or immediately targetable alterations have been reported from those studies.

A gene expression analysis suggested that BPDCN was similar to acute myeloid leukemia (AML), and identified the anti-apoptotic gene \textit{BCL2} as more highly expressed in BPDCN compared to normal pDCs (7). \textit{BCL2} is also expressed in AML and some AMLs are sensitive to the BCL-2 inhibitor venetoclax (8). Venetoclax has a favorable safety profile and was recently approved by the US Food and Drug Administration (FDA) for use in patients with relapsed chronic lymphocytic leukemia (CLL) (9). Here we demonstrate that BPDCN is dependent on BCL-2, and that venetoclax is active in BPDCN including in two patients with relapsed/refractory
disease. Thus, BCL-2 inhibition could provide a novel therapeutic strategy in this chemotherapy-resistant disease.

**Results**

We performed immunohistochemistry on BPDCN biopsies from bone marrow or skin, and in all cases we observed prominent BCL-2 staining compared to surrounding normal tissue (Figure 1A, Supplementary Figure 1). We saw similar BCL-2 expression in AML blasts from bone marrow and leukemia cutis (Supplementary Figure 1). These data suggested that, like AML, BPDCN might have some degree of BCL-2 dependence. However, cell death in response to BCL-2 inhibition depends on a complex balance of pro- and anti-apoptotic factors, which makes sensitivity prediction challenging based on expression alone (10).

Therefore, we performed functional mitochondrial profiling and conventional cytotoxicity assays to test BCL-2 inhibition in BPDCN. We first compared a BPDCN cell line, CAL1 (11), to a series of AML cell lines that have a range of sensitivity to BCL-2 inhibition (12). CAL1 cells expressed similar levels of BCL-2 protein to the highest BCL-2 expressing AML cells (Figure 1B), but there was variability in the abundance of other apoptotic pathway proteins. To assess the functional dependence of these cell lines on specific BCL-2 family members, we performed BH3 profiling. This technique exposes mitochondria to peptides that mimic the BH3 domain of pro-apoptotic BCL-2 family members and measures the induced change in mitochondrial permeability, the “point of no return” for apoptotic cell death (13).

We determined the propensity of each cell line to initiate mitochondrial apoptosis after stimulation with a non-specific pro-death BIM peptide (overall priming), and the relative dependency on three anti-apoptotic BCL-2 family members: BCL-2, BCL-XL, and MCL-1. CAL1 cells were most dependent on BCL-2, as they showed significant priming in response to BAD
stimulation (BCL-2/BCL-XL), but only minor priming after HRK (BCL-XL only) and none after MS1 (MCL-1) stimulation (Figure 1C). In contrast, AML cells were equally or less BCL-2 dependent, and/or were co-dependent on BCL-XL or MCL-1 in addition to BCL-2.

To directly measure responses to pharmacologic BCL-2 inhibition, we treated cells with venetoclax, a BH3 mimetic molecule that displaces pro-apoptotic proteins such as BIM from sequestration by BCL-2, allowing them to initiate mitochondrial permeabilization (14). We performed dynamic BH3 profiling (15), which measures the increase in apoptotic priming induced by incubation with a drug. Dynamic BH3 profiling strongly correlates with eventual induction of apoptotic cell death by the same treatment yet requires only short-term exposure to drug (<4 hours), which is advantageous in analyses of primary cells. By measuring the dose-dependent cytochrome c release induced by BIM peptide we calculated the change in overall apoptotic priming caused by venetoclax pretreatment (“delta priming”). CAL1 cells had an equal or higher delta priming compared with the AML cells tested (Figure 1D).

As predicted by this result, CAL1 cells were equally or more sensitive to venetoclax compared with AML cells in viability assays (Figure 1E). We confirmed that venetoclax induces dose-dependent apoptotic cell death in CAL1 cells by measuring Annexin V and propidium iodide staining following treatment (Supplementary Figure 2A-B). We also noted that dynamic BH3 profiling significantly correlated with Annexin V positivity in response to venetoclax (P=0.0067, Figure 1F), supporting the validity of this assay as a functional surrogate of drug sensitivity. The predictions made by BH3 profiling across all cell lines were also confirmed using navitoclax (ABT-263), which inhibits both BCL-2 and BCL-XL, and A-1331852, which targets BCL-XL only (16) (Supplementary Figure 3). Together, these data suggest that BPDCN cells are sensitive to venetoclax, at least in part because they are highly dependent on BCL-2 to inhibit mitochondrial apoptosis.
To test this hypothesis in primary cells, we analyzed patient bone marrow aspirates and skin biopsies involved by BPDCN, as well as BPDCN patient-derived xenografts (PDXs) (17). PDXs displayed pathological characteristics of human BPDCN, including infiltration of bone marrow and spleen by CD4+CD56+CD123+ leukemia cells that were also BCL-2 positive (Supplementary Figure 4). Patient tumor samples and PDXs were subjected to targeted DNA sequencing and represent a variety of genotypes (Supplementary Table 1).

Culturing primary leukemia cells in vitro to perform drug treatment assays is challenging. Ex vivo cytotoxicity assays with primary BPDCNs suggested a dose-dependent response to venetoclax in some cases (Supplementary Figure 5A-B), but maintaining viability even in vehicle-treated samples for more than 8 hours was not uniformly feasible. Therefore, we performed BH3 profiling in primary BPDCNs similarly to how we had done in cell lines. In addition, we used flow cytometry-based BH3 profiling to measure cytochrome c release in defined subpopulations of interest (18). Using this technique, we were able to selectively assess responses in leukemia cells admixed with normal cells. For comparison, we also tested a randomly selected set of primary AMLs. Baseline BCL-2/BCL-XL dependency was higher in BPDCN compared to AML (69.1% vs 2.1% priming by BAD peptide, P<0.0001 by t-test; Figure 2A). Similarly, when permeabilized cells were directly stimulated with equivalent doses of venetoclax, BPDCNs had a higher level of cytochrome c release than the AMLs tested (57.4% vs 2.62%, P=0.0001; Figure 2B).

Next, we used dynamic BH3 profiling to measure the change in apoptotic priming in response to venetoclax treatment of live cells with intact membranes. All BPDCNs had a significant increase in priming, or a decrease in their apoptotic threshold, after short-term treatment with venetoclax, and BPDCN priming was higher than in AML (59.8% vs 12.1%, P<0.0001; Figure 2C). Normal
bone marrow had significantly less priming than BPDCN in response to the same dose of venetoclax (18.5% vs 59.8%, P=0.0002; Figure 2C), suggesting a therapeutic window.

We performed an orthogonal assay for apoptotic cell death by measuring cell surface Annexin V in primary BPDCN and AML after short-term venetoclax treatment. On average, BPDCN had a greater increase in Annexin V positivity than AML (2.25-fold vs 1.2-fold, P=0.03; Figure 2D). Annexin V positivity was significantly correlated with the increase in priming measured by dynamic BH3 profiling (P=0.0088, Figure 2D). Together, these data suggest that BPDCN is highly BCL-2 dependent and predicts that BPDCN may be sensitive to venetoclax therapy.

To test BPDCN response to BCL-2 inhibition in vivo we transplanted two PDXs into recipient animals. When human BPDCN was detectable in blood, we randomized animals to treatment with venetoclax or vehicle for 28 days. After 21 days we sacrificed a subset for pharmacodynamic evaluation. Venetoclax treatment resulted in a reduced burden of human BPDCN cells in peripheral blood, bone marrow, and spleen (Figure 3A-B, Supplementary Figure 6). Histologic and immunohistochemical analyses confirmed decreased BPDCN in tissues, and showed restoration of normal hematopoietic elements in treated animals (Figure 3C). Animals receiving venetoclax had prolonged overall survival compared to vehicle-treated mice (median survival 57 vs 36 days, P=0.0025; Figure 3D).

We identified two patients with relapsed/refractory BPDCN who received therapy with venetoclax, prescribed off-label after the recent FDA approval in CLL. Both patients had no alternative therapeutic options and their treating physicians prescribed venetoclax because of the reports of BPDCN responding to “lymphoid-like” leukemia regimens (2) and because of venetoclax’s single-agent activity in AML (8). Patient #1 was an 80-year-old male diagnosed with BPDCN 18 months prior, and had disease involving bone marrow, lymph nodes, and
diffuse cutaneous plaques and tumors. His BPDCN harbored the following mutations: ASXL1 Y591fs*, GNB1 K57E, IDH2 R140W, and NRAS G12D. He previously responded to and then progressed on conventional chemotherapy (doxorubicin, vincristine, and prednisone), an IDH2-targeting agent, and an IL3-receptor targeting agent. Patient #2 was a 73-year-old male diagnosed with BPDCN 15 months prior, with skin, marrow, and widespread nodal involvement. His BPDCN harbored MPL Y591N, TET2 M1456fs*, and TET2 Q1654fs* mutations. He previously received and then relapsed after chemotherapy (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), an autologous stem cell transplant, an IL3-receptor targeting agent, and decitabine.

We had previously performed dynamic BH3 profiling on biopsies of skin (Patient #1) and bone marrow (Patient #2), which predicted that their disease would respond to venetoclax (BPDCN3 and 6, Figure 2B). Patient #1 received venetoclax orally with a weekly dose escalation of 20 mg, 50 mg, 100 mg, 200 mg, and finally 400 mg per day. He did not have any evidence of tumor lysis syndrome, despite rapid regression of visible tumors. At 4 weeks his disease was restaged, which revealed a marked response in multiple cutaneous sites of involvement (Figure 4A). His modified Severity Weighted Assessment Tool (mSWAT) skin scores decreased from 16.5 to 6.5. He had a decrease in the size of palpable cervical and preauricular lymph nodes, but did not have an appreciable response in his bone marrow at that time. Unfortunately, he died two weeks later with an intracranial hemorrhage before additional response evaluation could be performed. His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment and likely related to bone marrow infiltration by BPDCN.

Patient #2 received a daily dose escalation of venetoclax of 50 mg, 100 mg, 200 mg, to a final dose of 400 mg daily. He did not have any evidence of tumor lysis syndrome nor any other toxicity related to venetoclax. At 4 weeks, his skin disease had substantially improved, and a
PET-CT scan demonstrated a significant decrease in multistation lymphadenopathy and near complete resolution of all areas of FDG-avidity (Figure 4B-C). His bone marrow BPDCN blast count decreased from 85% pre-treatment to 44% after 6 weeks. He remained on venetoclax 400 mg daily for approximately 12 weeks, at which time he experienced disease progression.

**Discussion**

We have demonstrated that BPDCN is dependent on BCL-2 and is markedly sensitive to BCL-2 inhibition with venetoclax. Amongst the primary leukemias, PDXs, and cell lines we tested, BPDCN was at least as sensitive to BCL-2 inhibition compared with AML. The BPDCN response to venetoclax compares favorably with CLL, a disease that has shown remarkable single agent activity, including in relapsed patients with unfavorable genetics (9). BCL-2 inhibition should be formally evaluated in BPDCN as soon as possible, because there are few therapeutic options for these patients.

The mechanisms underlying BCL-2 dependence in BPDCN are unclear. There are no recurrent DNA copy number changes nor rearrangements reported involving the BCL2 locus (19,20), although additional analysis of BPDCN genomics may provide more insight into its BCL-2 dependency. Prior studies in AML have suggested that specific somatic mutations may be enriched in venetoclax-sensitive leukemias (8,21). Larger numbers of BPDCN patients treated with venetoclax with complete genetic annotation will be required to make definitive genotype-phenotype correlations in this disease. However, we note that the primary BPDCNs tested here harbored a variety of mutations in genes associated with hematologic malignancies (Supplementary Table 1), and all responded to venetoclax by BH3 profiling. Normal pDCs are selectively depleted *in vivo* by venetoclax compared to conventional dendritic cells (cDCs) and other hematopoietic cell types (22), suggesting that the sensitivity we observed could represent a lineage-specific dependency.
Finally, these data demonstrate precision cancer therapy directed by functional rather than genetic assessment. BH3 profiling served as a biomarker to identify BPDCN as dependent on BCL-2 and likely to respond to venetoclax. The same technique could be used in trials (in BPDCN or other cancers) evaluating venetoclax to determine if drug-resistant cells switch their dependency to another anti-apoptotic protein, which itself might be targetable. Furthermore, microenvironmental signals modulate apoptotic dependencies (22,23), which suggests that correlative studies in clinical trials could analyze BPDCN from distinct anatomical sites to elucidate additional mechanisms of response and resistance. Finally, combination of venetoclax with other agents should also be evaluated in BPDCN, given that BCL-2 inhibition may be synergistic with chemotherapy (24).
Acknowledgements

The authors thank Amanda Christie, Alexandra Christodoulou, David Weinstock, and the DFCI PDX repository (www.PRoXe.org) for helping with BPDCN xenografts; Takahiro Maeda (Nagasaki University) for sharing the CAL1 cell line; and Joel Leverson (AbbVie) for providing venetoclax, navitoclax, and A-1331852.

Grant Support

This work was supported by a DFCI Medical Oncology Research Grant (T.L., A.A.L), the Ludwig Cancer Research Foundation (J.S., J.C.A.), and an American Society of Hematology Scholar Award (A.A.L).
Methods

Cell lines
CAL1 cells were obtained from Takahiro Maeda (Nagasaki University) in 2012 (11). AML cell lines were obtained from ATCC or DSMZ between 2008-2014. They were validated by STR profiling in 2014 prior to their use in these experiments and they undergo mycoplasma testing every 6 months.

Patient samples
Primary BPDCN and AML cells were collected from patients who had consented to IRB-approved research protocols for sample analysis from patients with hematologic malignancies. Bone marrow aspirate mononuclear cells from BPDCN and AML patients were purified by Ficoll density centrifugation using standard procedures. Skin biopsies were exposed to an enzymatic digestion solution in 2.5 mL of DMEM/F12 media containing 125 U DNase I (Sigma Aldrich #DN25), 100 U hyaluronidase (Sigma Aldrich #H3506), and 300 U collagenase IV (Gibco #17104-019). The tissue suspension was processed using gentleMACS™ Dissociator (Miltenyl Biotec) using the hTUMOR 1 program. The suspension was then incubated at 37°C for 30 min with constant agitation. Then, dissociation was repeated using the hTUMOR 1 program, and the 30 min incubation was repeated. We then filtered the suspension through a 70 micron filter and cells were centrifuged at 400 x g for 5 min. To lyse residual red blood cells, 100 μL of ice cold water was added to the pellet for 15 sec and then diluted to 50 mL with PBS. Then, cells were centrifuged and resuspended in RPMI media for subsequent analysis.

Antibodies and Western blotting
Samples for Western blotting were prepared by lysing 10^6 cells in radioimmunoprecipitation assay buffer (RIPA, Boston Bioproducts, #BP-115) containing 1x protease inhibitor (ThermoFisher, cat. 87786). The antibodies used in were BCL-2 (BD Pharmingen, #551107),...
BCL-XL (Cell Signaling Technologies, #2764), MCL-1 (Cell Signaling Technologies, #5453),
BIM (Cell Signaling Technologies, #2933), BAX (#2774) and β-Actin (Sigma-Aldrich, #A5441).
Western blots were imaged using an ImageQuant LAS-4000 (GE Healthcare, #28-9558-10).

**Drug treatment of cell lines**
Cell lines cultured in RPMI-1640 with 10% FBS were plated in a 96-well dish at a concentration
of 5000 cells per 120 µL media. Compounds were added to the cells in serial five-fold dilutions.
After a 72 hr incubation at 37°C, viability was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. In brief, 40 µL of 5 mg/mL MTT (EMD Millipore,
#475989) was added to each well and incubated for 2 hrs, and then 100 µL MTT lysis buffer
was added to each well followed by additional 4 hr incubation. Absorbance values were
measured using a SpectraMax M3 plate reader (Molecular Devices) at 570 and 630 nm.
Viability curves values were generated using the nonlinear regression (curve fit) function in
GraphPad Prism (GraphPad Software, Inc.).

**Annexin V flow cytometry**
The cells were treated with drug for the indicated times, washed with Annexin V binding buffer
(ABB) and stained with 1:100 dilutions of Annexin V-FITC (Biolegend, #640906), CD45-APC
(BD Biosciences, #340943) and CD123-PerCP-Cy5.5 (BD Pharmingen, #560904) for 30 min.
Samples were the washed twice with ABB, propidium iodide (BD Pharmingen, #51-66211E)
was added after the last wash, and then cells were analyzed using a Cytoflex flow cytometer
(Beckman Coulter, #B53012).

**BH3 profiling**
Baseline and dynamic BH3 profiling were performed as described (13,15). Dynamic BH3
profiling was performed after 4 hrs of incubation of cell lines or primary leukemia cells in vehicle
or 100 nM venetoclax, unless otherwise specified. We used a flow cytometry-based BH3 profiling to perform the analysis, as previously described (18), using Zombie Aqua Dye (Biolegend, #423101) for viability, CD123-PerCP-Cy5.5 (BD Pharmingen, #560904), CD56-PECy7 (BD Pharmingen, #557747), and cytochrome c-Alexa Fluor 647 (Biolegend, #612310).

**Patient derived xenografts**

All animal experiments were approved by Institutional Animal Care and Use Committees. BPDCN PDXs were generated as described in the Dana-Farber Cancer Institute Public Repository of Xenografts ([PRoXe.org](http://PRoXe.org)) (17). For the treatment trial, one million cells from two independent PDXs (PDX1 and PDX4) were injected into 16 NSG-SGM3 mice each (NOD-Scid IL2Rgnull-3/GM/SF, NOD.Cg-PrkdcscidIl2rgtm1WjlTg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ, Jackson Labs #013062) each. Mice were monitored weekly for evidence of human BPDCN in the peripheral blood. When peripheral human CD45+CD123+ cells were more than 1% of total white blood cells, animals were randomized to two groups and treatment was started with vehicle or venetoclax 100 mg/kg/daily by oral gavage for 28 days. Three mice in each group were sacrificed at day 21 of treatment for pharmacodynamic assessment. The remaining animals were followed for survival. Both PDXs showed evidence of tumor response. PD and survival analysis for PDX4 is shown in Figure 3, and PDX1 in Supplementary Figure 4. Kaplan-Meier curves were compared using the log-rank test in GraphPad Prism. Immunohistochemistry was performed in the Dana-Farber/Harvard Cancer Center Specialized Histopathology Core Laboratory using standard protocols.

**DNA sequencing**

Patient samples were sequenced using a 95-gene targeted sequencing panel covering genes recurrently mutated in hematologic malignancies (25).
Venetoclax treatment

Patients with relapsed/refractory BPDCN who had exhausted other treatment options were prescribed venetoclax off-label by their treating physicians after they signed written informed consent. Prescriptions were filled in standard outpatient pharmacies after the FDA approval of venetoclax in 2016. The patients provided written informed consent to IRB-approved protocols for sample collection from patients with hematologic malignancies. They also signed additional specific consents for photographic data to be published, and all studies were in accordance with the Declaration of Helsinki. Patient #1 received oral venetoclax with a weekly dose escalation, starting at 20 mg daily for 7 days, followed by 50 mg daily for 7 days, 100 mg daily for 7 days, 200 mg daily for 7 days, followed by 400 mg daily. He was admitted to the hospital for the first dose initiation and the escalation to 50 mg to monitor for tumor lysis syndrome. Patient #2 received oral venetoclax with a daily dose escalation of 50 mg for one day, 100 mg for one day, 200 mg for one day, and then 400 mg daily. He was admitted to the hospital during the dose escalation to monitor for tumor lysis.
References


Figure Legends

Figure 1. BPDCN cells are dependent on BCL-2 and sensitive to venetoclax in vitro.
(A) Representative photomicrograph of a bone marrow biopsy demonstrating involvement with BPDCN by hematoxylin and eosin (H&E) staining and BCL-2 immunohistochemistry are shown. (B) Western blotting in BPDCN (CAL1) and AML (KASUMI1, OCI-AML2, THP1, MOLM13, U937, and TF1) cell lines is shown for the indicated anti- and pro-apoptotic proteins. (C) Baseline BH3 profiling is shown in the indicated cell lines. ‘Overall priming’ represents cytochrome c release in response to BIM peptide stimulation at four concentrations (0.03 μM, 0.1 μM, 0.3 μM, and 1 μM); ‘BCL-2/BCL-XL dependence,’ BAD peptide (10 μM, 100 μM); ‘BCL-XL dependence,’ HRK peptide (100 μM); and ‘MCL-1 dependence,’ MS1 peptide (10 μM). Graphs represent mean +/- SEM of 3 independent experiments. (D) Dynamic BH3 profiling depicting the difference in overall apoptotic priming before and after exposure to 100 nM venetoclax for 4 hours (‘delta priming’ or ‘Δ% priming’, graphs represent mean +/- SEM of 3 independent experiments, **P<0.01, ***P<0.001 vs CAL1 by t-test). (E) MTT assay results for the indicated cell lines after 72 hours of exposure to the indicated doses of venetoclax. Data points represent mean of 3 replicates +/- SEM, line represents non-linear regression (curve fit). (F) Correlation of 4 hour dynamic BH3 profiling with 24 hour percent cell death by Annexin V / propidium iodide flow cytometry after exposure to 100 nM venetoclax (Spearman r, and P values for correlation are shown).

Figure 2. BH3 profiling predicts venetoclax sensitivity in primary BPDCNs.
(A) Basal BH3 profiling showing cytochrome c release in response to 100 μM BAD peptide stimulation (normalized to DMSO control) in primary BPDCNs from patients and from PDXs, AMLs, and normal bone marrow (NBM). (B) Basal BH3 profiling in response to 1 μM venetoclax, as in (A). (C) Dynamic BH3 profiling depicting the difference in overall apoptotic
priming before and after exposure to 100 nM venetoclax for 4 hours. (D) Correlation of dynamic BH3 profiling delta priming with percent cell death by Annexin V / propidium iodide flow cytometry (Spearman r, and P values for correlation are shown).

**Figure 3. Animals bearing BPDCN patient-derived xenografts experience clinical response and prolonged survival after venetoclax treatment.**

(A) Pharmacodynamic (PD) assessment of spleen size and weight in six recipients of a representative PDX after 21 days of continuous treatment with vehicle (n=3) or venetoclax 100 mg/kg/daily (n=3). (B) PD assessment of percent human CD45+CD123+ cells in the peripheral blood (PB), spleen, and bone marrow (BM) of six animals bearing PDX4 after 21 days of treatment with vehicle (n=3) or venetoclax (n=3). (C) Bone marrow and splenic tissue stained with H&E and for human CD45 in animals bearing a BPDCN PDX after 21 days of treatment with vehicle or venetoclax. (D) Kaplan-Meier curves comparing overall survival of mice bearing PDX4 that received vehicle or venetoclax daily for days 10-37, as indicated by the gray bar (curves compared by log-rank test, n=5 mice/treatment arm).

**Figure 4. Venetoclax is active in patients with BPDCN.**

(A) Photographs of skin and gingival tumors in Patient #1 pre-treatment and after 4 weeks of venetoclax. (B) Photographs of Patient #2 after 5 days and 25 days of treatment with venetoclax. Photographs in panels A and B published with permission of the patients, given at the time the photo was taken. (C) PET-CT scan images from Patient #2 pre-treatment and after 4 weeks, showing a representative cross section in the neck/cervical spine, and whole body images with near complete resolution of FDG-avid lymphadenopathy in bilateral cervical and axillary lymph nodes (indicated by blue arrows), mediastium, abdomen, pelvis, and inguinal regions after treatment.
Supplementary Figure Legends

Supplementary Figure 1. BPDCN expresses BCL-2 protein.
Photomicrographs of H&E stains and BCL-2, CD123, and TCL-1 immunohistochemistry for BPDCN and AML biopsies from bone marrow and skin are shown. Each of the biopsies (each row) is from a different patient. The BPDCN from Figure 1A is re-presented here for comparison to other BPDCNs and AMLs.

Supplementary Figure 2. Venetoclax induces dose-dependent apoptotic cell death in BPDCN and AML cell lines.
(A) Representative Annexin V-FITC vs propidium iodide (PI) flow cytometry staining to measure apoptosis induction in CAL1 cells after 24 hours of exposure to vehicle, or 10 nM or 100 nM venetoclax are shown. (B) Quantitation of cell death by Annexin V and PI flow cytometry after 24 hours of exposure to the indicated concentrations of venetoclax. Graphs represent mean +/- SEM of 3 independent experiments, *P<0.05 by t-test compared to vehicle.

Supplementary Figure 3. Response of BPDCN and AML cells to navitoclax and A-1331852.
(A) MTT assay results for the indicated cell lines after 72 hours of exposure to the indicated doses of navitoclax (combined BCL-2/BCL-XL inhibitor). (B) MTT assay results for the indicated cell lines after 72 hours of exposure to the indicated doses of A-1331852 (BCL-XL only inhibitor). In both panels, data points represent mean of 3 replicates +/- SEM, line represents non-linear regression (curve fit).

Supplementary Figure 4. Pathological analysis of human BPDCN growing as a patient-derived xenograft (PDX) in mice.
Splenic tissue is shown stained with H&E (at 40x and 100x magnification), and human BCL-2, CD45, CD4, CD56, and CD123 (all at 40x) from animals bearing a representative BPDCN PDX.

**Supplementary Figure 5. Time and dose-dependent response of primary BPDCN to venetoclax *in vitro*.**

(A) Cell death measurement by flow cytometry at 4 and 8 hours after addition of venetoclax at the indicated doses in a primary BPDCN, represented as change in Annexin V positivity relative to vehicle. (B) Dose response of primary BPDCNs and AMLs to venetoclax *in vitro* measured as in (A).

**Supplementary Figure 6. Additional pharmacodynamic data showing *in vivo* PDX response to venetoclax.**

PD assessment of percent human CD45+CD123+ cells in the peripheral blood (PB), spleen, and bone marrow (BM) of six animals bearing PDX1 after 21 days of treatment with vehicle (n=3) or venetoclax (n=3).
Figure 1

A

H&E

BCL-2

B

C

CAL1

KASUMI1

OCI-AML2

THP1

MOLM13

U937

TF1

% priming

CAL1

KASUMI1

OCI-AML2

THP1

MOLM13

U937

TF1

% priming

D

Δ % priming

CAL1

KASUMI1

OCI-AML2

THP1

MOLM13

U937

TF1

E

Fraction alive

Log [venetoclax] (M)

CAL1

BCL-2

BCL-XL

MCL-1

BAX

BIM

Actin

F

% cell death

Δ % priming

CAL1

KASUMI1

OCI-AML2

THP1

MOLM13

U937

TF1

r = 0.9286

P = 0.0067
Figure 2

A

% priming (BAD peptide)

BPDCN  AML  NBM

B

% priming (venetoclax)

BPDCN  AML  NBM

C

Δ % priming (venetoclax)

BPDCN  AML  NBM

D

Fold change Annexin V+

r = 0.7321
P = 0.0088

BPDCN  AML

Δ % priming
Figure 3

A

![Image of spleen weights](image)

B

![Graph of percent BPDCN](image)

C

**Bone marrow**

- Vehicle
- Venetoclax

**Spleen**

- Vehicle
- Venetoclax

- H&E

- Human CD45

D

![Graph of percent survival](image)

- Treatment
- P = 0.0025
Figure 4

A. Pre-treatment 4 weeks

B. 5 days 25 days

C. Pre-treatment 3 weeks
Supplementary Figure 2

A

Vehicle 10 nM venetoclax 100 nM venetoclax

Annexin V - FITC Propidium iodide

B

% cell death

venetoclax (nM): 0 10 100 0 10 100 0 10 100 0 10 100 0 10 100 0 10 100

CAL1 KASUMI1 OCI-AML2 THP1 MOLM13 U937 TF1

* * * * * * *
Supplementary Figure 5

A

B

venetoclax (nM): 0 10 100 0 10 100

venetoclax (nM) 10 100

Fold change Annexin V+

4 hrs 8 hrs

Fold change Annexin V+

0.0 0.5 1.0 1.5 2.0 2.5

venetoclax (nM) 10 100

0 1

Fold change Annexin V+

2

BPDCN

AML

1.0 1.5 2.0 2.5

venetoclax (nM) 10 100

1.0 1.5 2.0 2.5

venetoclax (nM) 10 100
**Supplementary Table 1.** Genetic analysis of the primary BPDCNs and AMLs, and PDXs

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Diagnosis</th>
<th>Primary/PDX</th>
<th>Naïve/Relapsed</th>
<th>DNA mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPDCN1</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Naïve</td>
<td>FANCL Q11*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 D835H</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>JAK2 V617F</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SRSF2 P95L</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TP53 R213*</td>
</tr>
<tr>
<td>BPDCN2</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Relapsed</td>
<td>TET2 V1395fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 N281fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ZRSR2 Y175*</td>
</tr>
<tr>
<td>BPDCN3</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Relapsed</td>
<td>ASXL1 Y591fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ASXL1 G642fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ASXL1 E553fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GNB1 K57E</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IDH2 R140W</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NRAS G12D</td>
</tr>
<tr>
<td>BPDCN4</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Naïve</td>
<td>ASXL1 G642fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 Q769*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 L1886fs*</td>
</tr>
<tr>
<td>BPDCN5</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Relapsed</td>
<td>NRAS G12D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 S522G</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 P1732S</td>
</tr>
<tr>
<td>BPDCN6</td>
<td>BPDCN</td>
<td>Primary</td>
<td>Relapsed</td>
<td>MPL Y591N</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 M1456fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 Q1654fs*</td>
</tr>
<tr>
<td>PDX1</td>
<td>BPDCN</td>
<td>PDX</td>
<td>Naïve</td>
<td>IDH2 R140Q</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TP53 S241F</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TP53 C176Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ZRSR2 S188*</td>
</tr>
<tr>
<td>PDX2</td>
<td>BPDCN</td>
<td>PDX</td>
<td>Naïve</td>
<td>ASXL2 V366fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 K1947fs*</td>
</tr>
<tr>
<td>PDX3</td>
<td>BPDCN</td>
<td>PDX</td>
<td>Naïve</td>
<td>ASXL1 G643fs*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NRAS A146T</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 Q632*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 Q734*</td>
</tr>
<tr>
<td>ID</td>
<td>Subtype</td>
<td>Disease Status</td>
<td>Mutation(s)</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------------</td>
<td>-------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>PDX4</td>
<td>BPDCN</td>
<td>PDX</td>
<td>Naïve ASXL1 G646fs* NRAS G13D JAK2 V617F TET2 D1017fs* TET2 Q1687fs*</td>
<td></td>
</tr>
<tr>
<td>AML1</td>
<td>AML</td>
<td>Primary</td>
<td>Naïve IDH1 R132G NPM1 W288fs*</td>
<td></td>
</tr>
<tr>
<td>AML2</td>
<td>AML</td>
<td>Primary</td>
<td>Relapsed NRAS Q61K</td>
<td></td>
</tr>
<tr>
<td>AML3</td>
<td>AML</td>
<td>Primary</td>
<td>Naïve DNMT3A R882H RUNX1 L56S SETD2 T1077A</td>
<td></td>
</tr>
<tr>
<td>AML4</td>
<td>AML</td>
<td>Primary</td>
<td>Naïve PTPN11 D61N</td>
<td></td>
</tr>
<tr>
<td>AML5</td>
<td>AML</td>
<td>Primary</td>
<td>Naïve KRAS G12R</td>
<td></td>
</tr>
</tbody>
</table>